Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic Pathways
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Cyclacel Pharma (CYCC) Halted on LUDP
April 4, 2017 10:25 AM EDTCyclacel Pharma (NASDAQ: CYCC) Halted on LUDP
... MoreCyclacel Pharma (CYCC) Continues Monday's Surge Following Preclinical Anti-Cancer Data; Gains Another 40%
April 4, 2017 8:13 AM EDTCyclacel Pharma (NASDAQ: CYCC) adds to Monday's 75% gains after the company announced over the weekend the presentation by independent investigators of preclinical data demonstrating therapeutic potential of CYC065, the Company's second-generation, cyclin-dependent kinase (CDK) 2/9 inhibitor, as a targeted anti-cancer agent.
Shares are up another 40% in pre-open trade to $9.00.
... More
Cyclacel Pharma (CYCC) Surges Following Preclinical Data on CYC065
April 3, 2017 10:09 AM EDTCyclacel Pharma (NASDAQ: CYCC) adds to gains following earlier volatility trading halt and news over the weekend from AACR. Shares are up 54%
Cyclacel Pharma announced the presentation by independent investigators of preclinical data demonstrating therapeutic potential of CYC065, the Company's second-generation, cyclin-dependent kinase (CDK)... More
